AlzeCure Pharma Valuation Multiples

AlzeCure Pharma Overview

About AlzeCure Pharma

AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms NeuroRestore, Alzstatin, and Painless. The company's drug candidates include; ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, ACD679, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatments of severe pain in conditions such as osteoarthritis.

Founded

2012

HQ

Employees

11

Website

alzecurepharma.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($5M)

EV

$12M

Valuation Multiples

Multiples.vc

Start free trial

AlzeCure Pharma Financials

AlzeCure Pharma reported last 12-month revenue of — and negative EBITDA of ($5M).

In the same LTM period, AlzeCure Pharma generated — in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).

AlzeCure Pharma P&L

In the most recent fiscal year, AlzeCure Pharma reported revenue of — and EBITDA of ($5M).

AlzeCure Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

AlzeCure Pharma Stock Performance

AlzeCure Pharma has current market cap of $18M, and enterprise value of $12M.

AlzeCure Pharma's stock price is $0.15.

AlzeCure Pharma Valuation Multiples

AlzeCure Pharma trades at (2.4x) EV/EBITDA.

AlzeCure Pharma Financial Valuation Multiples

As of April 18, 2026, AlzeCure Pharma has market cap of $18M and EV of $12M.

Equity research analysts estimate AlzeCure Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

AlzeCure Pharma has a P/E ratio of (3.4x).

AlzeCure Pharma Margins & Growth Rates

AlzeCure Pharma's revenue in the last fiscal year grew by —.

AlzeCure Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

AlzeCure Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

AlzeCure Pharma M&A Activity

AlzeCure Pharma acquired XXX companies to date.

Last acquisition by AlzeCure Pharma was on XXXXXXXX, XXXXX. AlzeCure Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

AlzeCure Pharma Investment Activity

AlzeCure Pharma invested in XXX companies to date.

AlzeCure Pharma made its latest investment on XXXXXXXX, XXXXX. AlzeCure Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).